Study of the Immune Correlates of Protection in Rhesus Macaques Vaccinated against Simian Immunodeficiency Virus
Repository URI
Repository DOI
Change log
Authors
Abstract
After more than thirty years since the Human Immunodeficiency Virus (HIV) was identified, only the RV144 phase III vaccine clinical trial provided evidence of protection from virus infection, with 31.2% of the patients protected at three years since the end of the immunisation phase. Statistical analyses support serum IgG antibody recognition of the V2 region of viral gp120 as a mechanism of protection from acquisition. One hypothesis is that antibodies to this region might block the interaction with the integrin
These results provide insights into possible mechanisms of protection of RV144 vaccination against HIV. Furthermore, these findings suggest that there may be a degree of structural plasticity of the V2 region that may impact its interaction with